Medina raises $7.7M Series B to fuel neurovascular disease device work; Codman Neuro faces Class I recall for liquid embolic system;

@FierceMedDev: Special Report: 2013's top FDA approvals in med tech. Report | Follow @FierceMedDev

@MarkHFierce: Check out the latest issue of FierceDiagnostics, now with expanded biomarker coverage. Issue | Follow @MarkHFierce

@MichaelGFierce: NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Covidien gets FDA OK for LigaSure laparoscopic surgical device. News | Follow @EmilyWFierce

> California's Medina Medical said it raised $7.7 million in a Series B preferred financing round to propel development of its embolization devices to treat neurovascular disease. Item

> Case Western Reserve University and University Hospitals Case Medical Center are developing a better imaging method to help assess stents placed in coronary arteries. The NIH is fueling the effort with a $1.7 million grant. Item

> The Bay State's Codman Neuro disclosed that the FDA has assigned Class I recall status to its Trufill n-BCA liquid embolic system--the agency's most serious. Codman issued a global medical device correction notice after reports that the mix could solidify too slowly and harm patients. Item

> EndoChoice won Canadian regulatory approval to start marketing its Fuse endoscopy system. Item

> Toronto's Amorfix Life Sciences has inked a deal with "a major global pharmaceutical copany" to use its Alzheimer's disease diagnostic assay in a clinical trial that will test a novel Alzheimer's treatment. Item

Biotech News

@FierceBiotech: The dethroned 'King of Biotech' will stay exiled in prison. News | Follow @FierceBiotech

@JohnCFierce: The 4th quarter was big--Q4 venture haul pushes 2013 biotech investing past $4.5B--and the year was fine, overall. Story | Follow @JohnCFierce

@DamianFierce: Your chance to vote: Who are the most influential people in biopharma today? Survey | Follow @DamianFierce

@EmilyMFierce: ICYMI, yesterday's edition of FierceBiotech Research featured Alzheimer's research and new nanotech. Read | Follow @EmilyMFierce

> Boehringer, Zealand hit reset on GLP-1 diabetes program. More

> U.K. mulls a 'breakthrough' drug program of its own. Article

> Yale researchers chide the FDA for failing to enforce high R&D standards. Coverage

Pharma News

@FiercePharma: What's a $2.9B deal + increasing sales equal? One enthused new CEO at Forest. Yesterday's story | Follow @FiercePharma

@TracyStaton: Here's my story on yesterday's Swiss job shuffle. Story | Follow @TracyStaton

@EricPFierce: Who do you think are the most influential people in biopharma? Like to see someone from manufacturing. Survey | Follow @EricPFierce

@CarlyHFierce: Vivus has lost more than half its board, its CFO, 2 CEOs and 20 staffers--and now its commercial chief, apparently. More | Follow @CarlyHFierce

> Now it's New York: Novartis eyes another 500-plus job cuts with plant shutdown. News

> Appeals court gives GSK another shot at AbbVie in HIV drug-pricing fight. Story

> Sanofi's MS pill Aubagio wins final thumbs-up from U.K. cost-effectiveness watchdogs. More

> Par Pharma nabs injectables specialist JHP for $490M in private-equity auction. Report

Drug Delivery News

> Nano-scaffold delivers genetic treatment to spur blood vessel growth. News

> Biotronik launches drug-releasing balloon Passeo-18 Lux in Europe. Article

> NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story

> Rooted delivery vehicles use electric charge and gravity to release drugs over time. Piece

> Statins delivered with HDL nanoparticles reduce risk of second heart attack, stroke. Story

> Novartis launches joint pain gel in India with Phosphagenics' delivery tech. Item

Diagnostics News

> Researchers from Singapore and China find a new esophageal cancer biomarker. More

> A finger-prick blood test could uncover sports concussions on the field. Article

> Myriad Genetics will market a breast cancer Dx made by a Siemens spinoff. Story

> FDA approves Affymetrix's blood test for developmental disabilities. Coverage

> Illumina brings next-generation sequencing to Amgen companion Dx deal. News

> LabCorp CEO promises continued rollout of new genomics-based Dx tests. Item

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.